| Literature DB >> 23712328 |
Syma Iqbal1, Heinz-Josef Lenz, David R Gandara, Stephen I Shibata, Susan Groshen, Timothy W Synold, Edward M Newman.
Abstract
The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m² preceded by escalating doses of docetaxel 60 mg/m² (75, 90, 100 mg/m²) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m² with oxaliplatin 130 mg/m².Entities:
Mesh：
Substances：
Year: 2013 PMID： 23712328 PMCID： PMC3779138 DOI： 10.1007/s00280-013-2171-4
Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333